Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

Circumstances of FDA's approval of Sarepta's Exondys 51 approval may give BioMarin reason to appeal the complete response for its Duchenne muscular dystrophy treatment drisapersen – but its high-quality data could preclude success.

BioMarin Pharmaceutical Inc. seems interested in taking advantage of the precedent Center for Drug Evaluation and Research Director Janet Woodcock created with her approval of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy treatment Exondys 51 (eteplirsen).

BioMarin is considering appealing the complete response letter for its Duchenne treatment drisapersen, proposed trade name Kyndrisa, and potentially looking...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet